Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Lonza ends biosimilars deal with Teva

Chemical firm cuts losses after four-year development deal

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Roche - Basel

Roche antibody tops Rituxan in blood cancer CLL

Obinutuzumab on course for leukaemia approval by year-end

- PMLiVE

NICE demands more data from Roche for MabThera in rare autoimmune disease

Unable to recommend expanding drug’s indication to include vasculitis

- PMLiVE

Analysts question value of rumoured $20bn Roche bid for Alexion

Shares in orphan drug specialist slide back after earlier surge

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

Roche - Basel

Late-stage blow to Roche’s diabetes ambitions

Halts development of aleglitazar on safety and efficacy concerns

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

Croatia joins European medicines network

Follows country's membership of the European Union

Roche - Basel

Roche’s blood cancer antibody wins priority review in US

Obinutuzumab is fast-tracked by FDA in treatment of chronic lymphocytic leukaemia

- PMLiVE

Roche pays $220m for blood-testing company

Boosts diagnostics business with acquisition of Constitution Medical Investors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links